Vergelijking

Eloralintide vs. Pramlintid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

151126-32-8

Molecuulmassa

geen gegevens

3949.4 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Eloralintide	Pramlintid
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Eloralintide

Volledige vermelding →

Pramlintid

Volledige vermelding →

Frequently asked questions

What is the difference between Eloralintide and Pramlintid?: Eloralintide is classified as "Metabool", while Pramlintid is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Pramlintid?: The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Pramlintid in Germany and the United States?: Duitsland: Eloralintide — Niet goedgekeurd, Pramlintid — Niet goedgekeurd. Verenigde Staten: Eloralintide — Niet goedgekeurd, Pramlintid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Pramlintid

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Eloralintide and Pramlintid?

Eloralintide is classified as "Metabool", while Pramlintid is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Pramlintid?

The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Pramlintid in Germany and the United States?

Duitsland: Eloralintide — Niet goedgekeurd, Pramlintid — Niet goedgekeurd. Verenigde Staten: Eloralintide — Niet goedgekeurd, Pramlintid — Op recept. These are factual summaries with source and review date on the individual pages.